Oxford Biomedica/£OXB
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Oxford Biomedica
Ticker
£OXB
Sector
Primary listing
LSE
Employees
900
Headquarters
Website
Oxford Biomedica Metrics
BasicAdvanced
£747M
-
-£0.36
0.95
-
Price and volume
Market cap
£747M
Beta
0.95
52-week high
£6.85
52-week low
£3.48
Average daily volume
221K
Financial strength
Current ratio
1.891
Quick ratio
1.592
Long term debt to equity
307.993
Total debt to equity
322.112
Interest coverage (TTM)
-2.28%
Profitability
EBITDA (TTM)
-12.566
Gross margin (TTM)
44.12%
Net profit margin (TTM)
-24.51%
Operating margin (TTM)
-18.15%
Effective tax rate (TTM)
-4.07%
Revenue per employee (TTM)
£170,000
Management effectiveness
Return on assets (TTM)
-7.44%
Return on equity (TTM)
-75.20%
Valuation
Price to revenue (TTM)
4.335
Price to book
20.14
Price to tangible book (TTM)
78.36
Price to free cash flow (TTM)
-54.488
Free cash flow yield (TTM)
-1.84%
Free cash flow per share (TTM)
-0.116
Growth
Revenue change (TTM)
55.44%
Earnings per share change (TTM)
-74.65%
3-year revenue growth (CAGR)
6.39%
10-year revenue growth (CAGR)
27.54%
3-year earnings per share growth (CAGR)
8.95%
10-year earnings per share growth (CAGR)
6.20%
What the Analysts think about Oxford Biomedica
Analyst ratings (Buy, Hold, Sell) for Oxford Biomedica stock.
Bulls say / Bears say
Oxford Biomedica reported a 38–44% year-on-year increase in H1 2025 revenues to £70–73 million, secured £149 million in new client orders (up from £56 million), and built a £222 million revenue backlog, supporting its reiterated full-year guidance of £160–170 million in revenue and low-single-digit operating EBITDA profitability. (Reuters)
On 1 August 2025, OXB secured a four-year loan facility of up to $125 million from Oaktree Capital Management—including $60 million upfront to refinance existing debt—improving its financial flexibility to support its global CDMO growth strategy. (Reuters)
Following the £60 million placing in August 2025, chair Dr Roch Doliveux purchased 67,000 shares at 449.75 pence, signaling strong insider confidence in OXB’s long-term growth prospects. (FT)
Despite strong commercial momentum, OXB recorded an £8.3 million operating EBITDA loss in H1 2025, highlighting its continuing lack of profitability. (Reuters)
Gross cash of £53.9 million as of 30 June 2025 provides limited funding for OXB’s capital-intensive capacity expansion plans. (Reuters)
The August 2025 placing issued 13.9 million new shares at 431 pence, a 1.9 percent discount, diluting existing shareholders by over 13 percent. (FT)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Oxford Biomedica Financial Performance
Revenues and expenses
Oxford Biomedica Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oxford Biomedica stock?
Oxford Biomedica (OXB) has a market cap of £747M as of November 10, 2025.
What is the P/E ratio for Oxford Biomedica stock?
The price to earnings (P/E) ratio for Oxford Biomedica (OXB) stock is 0 as of November 10, 2025.
Does Oxford Biomedica stock pay dividends?
No, Oxford Biomedica (OXB) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next Oxford Biomedica dividend payment date?
Oxford Biomedica (OXB) stock does not pay dividends to its shareholders.
What is the beta indicator for Oxford Biomedica?
Oxford Biomedica (OXB) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.